Here's What Key Metrics Tell Us About Workday (WDAY) Q2 Earnings

Workday (WDAY) reported strong Q2 2025 results, with revenue of $2.35 billion (+12.6% YoY) and EPS of $2.21, both surpassing analyst estimates. However, the company's Subscription Revenue Backlog of $25.37 billion missed the $26.48 billion consensus, and professional services revenue saw a slight year-over-year decline. This mixed performance, alongside a recent 5.6% stock decline and a Zacks #4 (Sell) rating, indicates potential investor caution despite the headline earnings beats.

Analysis

Workday's Q2 2025 earnings present a mixed picture, with strong headline figures masking potential underlying weakness. The company surpassed consensus estimates, reporting revenue of $2.35 billion, a 12.6% year-over-year increase, and an EPS of $2.21, a 5.74% beat. However, a critical forward-looking metric, the Subscription Revenue Backlog, came in at $25.37 billion, significantly missing the $26.48 billion analyst estimate. This suggests a potential deceleration in future revenue growth. While the core subscription services revenue grew a robust 14% year-over-year to $2.17 billion, professional services revenue contracted by 1.7% to $179 million, also falling short of expectations. This combination of a backlog miss and a decline in professional services, often a leading indicator for new business, points to possible headwinds. The market appears to be pricing in these concerns, as evidenced by the stock's -5.6% return over the past month, which sharply underperforms the S&P 500 composite's +1.7% gain, and the current Zacks Rank #4 (Sell) designation.

Key Decisions for Investors

• Investors should prioritize the significant miss in the subscription revenue backlog over the headline earnings beat, as this is a more critical indicator of the company's future growth pipeline.
• The 1.7% year-over-year decline in professional services revenue warrants caution, as it could signal a slowdown in new customer implementations or heightened competitive pressures.
• Given the stock's recent underperformance and its Zacks Rank #4 (Sell), maintaining a neutral or underweight position may be prudent until there is evidence of a re-acceleration in backlog growth.